DAWN vs NDAQ · rev $131.2M vs P/E 41, rev $2.53B
Day One Biopharmaceuticals Inc (DAWN) versus Nasdaq Inc (NDAQ) — a side-by-side from cached financials, not a winner call.
Day One Biopharmaceuticals Inc (DAWN) is a biotechnology company listed on US.
Nasdaq Inc (NDAQ) is a financial data & stock exchanges company listed on US.
Latest reported DAWN revenue for 2024-12-31 was $131.2M. Net income was -$95.5M. DAWN currently screens at market cap $656.8M.
Latest reported NDAQ revenue for 2026-06-30 was $2.53B. Net income was $507.0M. Revenue was up 18.5% from 2026-03-31 to 2026-06-30. NDAQ currently screens at market cap $51.71B and trailing P/E 40.8.
DAWN currently screens at market cap $656.8M. NDAQ currently screens at market cap $51.71B and trailing P/E 40.8.
Not investment advice. Open the DAWN and NDAQ stock pages for the full models.
Not investment advice.